DekaBank Deutsche Girozentrale raised its position in Illumina, Inc. (NASDAQ:ILMN) by 4.8% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 88,667 shares of the life sciences company’s stock after buying an additional 4,033 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Illumina were worth $15,751,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares during the last quarter. Jennison Associates LLC boosted its position in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Geode Capital Management LLC boosted its position in Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock worth $248,460,000 after buying an additional 107,941 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Illumina by 3.9% in the first quarter. Legal & General Group Plc now owns 651,314 shares of the life sciences company’s stock worth $111,142,000 after buying an additional 24,613 shares during the last quarter. 93.81% of the stock is owned by institutional investors.

Illumina, Inc. (ILMN) opened at 194.25 on Friday. The stock has a market capitalization of $28.36 billion, a price-to-earnings ratio of 38.97 and a beta of 0.83. The company has a 50-day moving average price of $179.63 and a 200-day moving average price of $173.73. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the prior year, the company earned $0.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/13/dekabank-deutsche-girozentrale-has-15-75-million-stake-in-illumina-inc-ilmn.html.

A number of equities analysts recently weighed in on ILMN shares. Deutsche Bank AG set a $175.00 price target on Illumina and gave the stock a “hold” rating in a report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and upped their price target for the stock from $170.00 to $215.00 in a report on Monday, August 7th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a report on Wednesday, June 21st. Morgan Stanley reissued an “underweight” rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a report on Monday, July 10th. Finally, Barclays PLC reissued a “hold” rating and set a $150.00 target price on shares of Illumina in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $177.01.

In related news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total transaction of $1,950,000.00. Following the completion of the sale, the senior vice president now directly owns 76,585 shares of the company’s stock, valued at approximately $14,934,075. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $184.75, for a total transaction of $26,788.75. Following the sale, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,010 shares of company stock valued at $23,946,015. 1.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.